The insulin receptor: A new target for cancer therapy

Frontiers in Endocrinology

Volumn 2, Issue DEC, 2011, Pages

  Malaguarnera, Roberta ^a   Belfiore, Antonino ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer; Igf i; IGF I receptor; Igf ii; Insulin receptor; Insulin resistance; IR isoform A; Target therapy

Indexed keywords

EID: 84874386146     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00093     Document Type: Review

References (198)

1. Aggarwal, R. R., Ryan, C. J., and Chan, J. M. (2011). Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol. Oncol.doi: 10.1016/j.urolonc.2011.05.001.
2. Aiello, A., Pandini, G., Frasca, F., Conte, E., Murabito, A., Sacco, A., Genua, M., Vigneri, R., and Belfiore, A. (2006). Peroxisomal proliferator-activated receptorgamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147, 4463-4475.
3. Aiello, A., Pandini, G., Sarfstein, R., Werner, H., Manfioletti, G., Vigneri, R., and Belfiore, A. (2010). HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur. J. Cancer 46, 1919-1926.
4. Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., and Thor, A. D. (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8, 909-915.
5. Andersen, A. S., Wiberg, F. C., and Kjeldsen, T. (1995). Localization of specific amino acids contributing to insulin specificity of the insulin receptor. Ann. N. Y. Acad. Sci. 766, 466-468.
6. Arbet-Engels, C., Tartare-Deckert, S., and Eckhart, W. (1999). C-terminal Src kinase associates with ligandstimulated insulin-like growth factor-I receptor. J. Biol. Chem. 274, 5422-5428.
7. Armengol, G., Knuutila, S., Lluis, F., Capella, G., Miro, R., and Caballin, M. R. (2000). DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet. Cytogenet. 116, 133-141.
8. Atzori, F., Tabernero, J., Cervantes, A., Prudkin, L., Andreu, J., RodriguezBraun, E., Domingo, A., Guijarro, J., Gamez, C., Rodon, J., Di Cosimo, S., Brown, H., Clark, J., Hardwick, J., Beckman, R. A., Hanley, W., Hsu, K., Calvo, E., Rosello, S., Langdon, R. B., and Baselga, J. (2011). A phase I, pharmacokinetic and pharmacodynamic study of dalotuzumab (MK0646), an Anti-IGF-1R monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 17, 6304-6312.
9. Baron, V., Calleja, V., Ferrari, P., Alengrin, F., and Van Obberghen, E. (1998). p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors. J. Biol. Chem. 273, 7162-7168.
10. Beitner-Johnson, D., and LeRoith, D. (1995). Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. J. Biol. Chem. 270, 5187-5190.
11. Belfiore, A. (2007). The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des. 13, 671-686.
12. Belfiore, A., Costantino, A., Frasca, F., Pandini, G., Mineo, R., Vigneri, P., Maddux, B., Goldfine, I. D., and Vigneri, R. (1996). Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Mol. Endocrinol. 10, 1318-1326.
13. Belfiore, A., and Frasca, F. (2008). IGF and insulin receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 381-406.
14. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., and Vigneri, R. (2009a). Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586-623.
15. Belfiore, A., Genua, M., and Malaguarnera, R. (2009b). PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res. 2009, 830501.
16. Bendall, S. C., Stewart, M. H., Menendez, P., George, D., Vijayaragavan, K., Werbowetski-Ogilvie, T., RamosMejia, V., Rouleau, A., Yang, J., Bosse, M., Lajoie, G., and Bhatia, M. (2007). IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 448, 1015-1021.
17. Benyoucef, S., Surinya, K. H., Hadaschik, D., and Siddle, K. (2007). Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem. J. 403, 603-613.
18. Bereziat, V., Kasus-Jacobi, A., Perdereau, D., Cariou, B., Girard, J., and Burnol, A. F. (2002). Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14. J. Biol. Chem. 277, 4845-4852.
19. Blanco-Aparicio, C., Renner, O., Leal, J. F., and Carnero, A. (2007). PTEN, more than the AKT pathway. Carcinogenesis 28, 1379-1386.
20. Bo, S., Ciccone, G., Rosato, R., Villois, P., Appendino, G., Ghigo, E., and Grassi, G. (2011). Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. Diabetes Obes. Metab.doi: 10.1111/j.1463-1326.2011.01480.x.
21. Bosco, J. L., Antonsen, S., Sorensen, H. T., Pedersen, L., and Lash, T. L. (2011). Metformin and incident breast cancer among diabetic women: a population-based casecontrol study in Denmark. Cancer Epidemiol. Biomarkers Prev. 20, 101-111.
22. Bowker, S. L., Majumdar, S. R., Veugelers, P., and Johnson, J. A. (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258.
23. Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S., and Pouyssegur, J. (1999). Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factorinduced gene expression and cell cycle entry. EMBO J. 18, 664-674.
24. Buck, E., and Mulvihill, M. (2011). Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin. Investig. Drugs 20, 605-621.
25. Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., and Winer, E. P. (2003). Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat. 79, 391-397.
26. Butler, R., Mitchell, S. H., Tindall, D. J., and Young, C. Y. (2000). Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferatoractivated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ. 11, 49-61.
27. Byron, S. A., Horwitz, K. B., Richer, J. K., Lange, C. A., Zhang, X., and Yee, D. (2006). Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br. J. Cancer 95, 1220-1228.
28. Canonici, A., Steelant, W., Rigot, V., Khomitch-Baud, A., BoutaghouCherid, H., Bruyneel, E., Van Roy, F., Garrouste, F., Pommier, G., and Andre, F. (2008). Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int. J. Cancer 122, 572-582.
29. Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, C., Cantor, G. H., Dell-John, J., Chen, C., Discenza, L., Menard, K., Li, A., Trainor, G., Vyas, D., Kramer, R., Attar, R. M., and Gottardis, M. M. (2009). BMS754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8, 3341-3349.
30. Carden, C. P., Kim, E. S., Jones, R. L., Alam, S. M., Johnson, F. M., Stephens, A. W., Poondru, S., Gedrich, R., Lippman, S. M., and Kaye, S. B. (2010). Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J. Clin. Oncol. 28, abstr. 2530.
31. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285-4289.
32. Casa, A. J., Dearth, R. K., Litzenburger, B. C., Lee, A. V., and Cui, X. (2008). The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front. Biosci. 13, 3273-3287.
33. Ceresa, B. P., and Pessin, J. E. (1998). Insulin regulation of the Ras activation/inactivation cycle. Mol. Cell. Biochem. 182, 23-29.
34. Chua, H. L., Bhat-Nakshatri, P., Clare, S. E., Morimiya, A., Badve, S., and Nakshatri, H. (2007). NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB1 and ZEB-2. Oncogene 26, 711-724.
35. Colhoun, H. M. (2009). Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52, 1755-1765.
36. Corpet, D. E., Jacquinet, C., Peiffer, G., and Tache, S. (1997). Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr. Cancer 27, 316-320.
37. Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J., and Thun, M. J. (2004). Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am. J. Epidemiol. 159, 1160-1167.
38. Craparo, A., Freund, R., and Gustafson, T. A. (1997). 14-3-3 (Epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserinedependent manner. J. Biol. Chem. 272, 11663-11669.
39. Currie, C. J., Poole, C. D., and Gale, E. A. (2009). The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777.
40. Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., Defronzo, R. A., Kahn, C. R., and Mandarino, L. J. (2000). Insulin resistance differentially affects the PI 3-kinaseand MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 105, 311-320.
41. Dalle, S., Ricketts, W., Imamura, T., Vollenweider, P., and Olefsky, J. M. (2001). Insulin and insulinlikegrowthfactorIreceptorsutilize different G protein signaling components. J. Biol. Chem. 276, 15688-15695.
42. de Bono, J. S., Attard, G., Adjei, A., Pollak, M. N., Fong, P. C., Haluska, P., Roberts, L., Melvin, C., Repollet, M., Chianese, D., Connely, M., Terstappen, L. W., and Gualberto, A. (2007). Potential applications for circulating tumor cells expressing the insulinlikegrowthfactor-Ireceptor. Clin. Cancer Res. 13, 3611-3616.
43. Denley, A., Bonython, E. R., Booker, G. W., Cosgrove, L. J., Forbes, B. E., Ward, C. W., and Wallace, J. C. (2004). Structural determinants for high-affinity binding of insulinlike growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol. Endocrinol. 18, 2502-2512.
44. Denley, A., Carroll, J. M., Brierley, G. V., Cosgrove, L., Wallace, J., Forbes, B., and Roberts, C. T. Jr. (2007). Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol. Cell. Biol. 27, 3569-3577.
45. Dinchuk, J. E., Cao, C., Huang, F., Reeves, K. A., Wang, J., Myers, F., Cantor, G. H., Zhou, X., Attar, R. M., Gottardis, M., and Carboni, J. M. (2010). Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807. Endocrinology 151, 4123-4132.
46. Dong, J., Demarest, S. J., Sereno, A., Tamraz, S., Langley, E., Doern, A., Snipas, T., Perron, K., Joseph, I., Glaser, S. M., Ho, S. N., Reff, M. E., and Hariharan, K. (2010). Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol. Cancer Ther. 9, 2593-2604.
47. Drakas, R., Tu, X., and Baserga, R. (2004). Control of cell size through phosphorylation of upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 101, 9272-9276.
48. Drejer, K. (1992). The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab. Rev. 8, 259-285.
49. Duggan, C., Irwin, M. L., Xiao, L., Henderson, K. D., Smith, A. W., Baumgartner, R. N., Baumgartner, K. B., Bernstein, L., BallardBarbash, R., and Mctiernan, A. (2011). Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J. Clin. Oncol. 29, 32-39.
50. Dunn, S. E., Hardman, R. A., Kari, F. W., and Barrett, J. C. (1997). Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 57, 2687-2693.
51. Dupont, J., Fernandez, A. M., Glackin, C. A., Helman, L., and Leroith, D. (2001). Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J. Biol. Chem. 276, 26699-26707.
52. Ebina, Y., Edery, M., Ellis, L., Standring, D., Beaudoin, J., Roth, R. A., and Rutter, W. J. (1985). Expression of a functional human insulin receptor from a cloned cDNA in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U.S.A. 82, 8014-8018.
53. Economou, M. A., Andersson, S., Vasilcanu, D., All-Ericsson, C., Menu, E., Girnita, A., Girnita, L., Axelson, M., Seregard, S., and Larsson, O. (2008). Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF1R expression and growth of uveal melanoma. Invest. Ophthalmol. Vis. Sci. 49, 2337-2342.
54. Evans, T., Lindsay, C. R., Chan, E., Tait, B., Michael, S. A., Day, S., Stephens, A. W., Franke, A., Poondru, S., and Puzanov, I. (2010). Phase I doseescalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. J. Clin. Oncol. 28, abstr. 2531.
55. Fair, A. M., Dai, Q., Shu, X. O., Matthews, C. E., Yu, H., Jin, F., Gao, Y. T., and Zheng, W. (2007). Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detect. Prev. 31, 214-219.
56. Faria, T. N., Blakesley, V. A., Kato, H., Stannard, B., Leroith, D., and Roberts, C. T. Jr. (1994). Role of the carboxyl-terminal domains of the insulin and insulin-like growth factor I receptors in receptor function. J. Biol. Chem. 269, 13922-13928.
57. Feng, Y., Zhu, Z., Xiao, X., Choudhry, V., Barrett, J. C., and Dimitrov, D. S. (2006). Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol. Cancer Ther. 5, 114-120.
58. Ferrara, A., Lewis, J. D., Quesenberry, C. P. Jr., Peng, T., Strom, B. L., Van Den Eeden, S. K., Ehrlich, S. F., and Habel, L. A. (2011). Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34, 923-929.
59. Fierz, Y., Novosyadlyy, R., Vijayakumar, A., Yakar, S., and Leroith, D. (2010). Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59, 686-693.
60. Foti, D., Iuliano, R., Chiefari, E., and Brunetti, A. (2003). A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol. Cell. Biol. 23, 2720-2732.
61. Frasca, F., Pandini, G., Malaguarnera, R., Mandarino, A., Messina, R. L., Sciacca, L., Belfiore, A., and Vigneri, R. (2007). Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J. Biol. Chem. 282, 26077-26088.
62. Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., and Vigneri, R. (1999). Insulin receptor isoform A, a newly recognized, highaffinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 19, 3278-3288.
63. Furlanetto, R. W., Dey, B. R., Lopaczynski, W., and Nissley, S. P. (1997). 14-3-3 Proteins interact with the insulin-like growth factor receptor but not the insulin receptor. Biochem. J. 327(Pt 3), 765-771.
64. Gao, J., Chesebrough, J. W., Cartlidge, S. A., Ricketts, S. A., Incognito, L., Veldman-Jones, M., Blakey, D. C., Tabrizi, M., Jallal, B., Trail, P. A., Coats, S., Bosslet, K., and Chang, Y. S. (2011). Dual IGFI/II-neutralizing antibody MEDI573 potently inhibits IGF signaling and tumor growth. Cancer Res. 71, 1029-1040.
65. Garofalo, C., Manara, M. C., Nicoletti, G., Marino, M. T., Lollini, P. L., Astolfi, A., Pandini, G., LopezGuerrero, J. A., Schaefer, K. L., Belfiore, A., Picci, P., and Scotlandi, K. (2011). Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30, 2730-2740.
66. Gedrich, R., Poondru, S., Stephens, A., Logan, T., Hart, K., Buck, E., Carden, C., Lindsay, C., Kaye, S., Kim, E., Evans, J., Puzanov, I., Epstein, D., and Miglarese, M. (2009). Pharmacodynamic biomarkers for OSI-906, an insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors. Mol. Cancer Ther. 8, abstr. A46.
67. Giorgino, F., Belfiore, A., Milazzo, G., Costantino, A., Maddux, B., Whittaker, J., Goldfine, I. D., and Vigneri, R. (1991). Overexpression of insulin receptors in fibroblast and ovary cells induces a ligandmediated transformed phenotype. Mol. Endocrinol. 5, 452-459.
68. Girnita, A., Girnita, L., Del Prete, F., Bartolazzi, A., Larsson, O., and Axelson, M. (2004). Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64, 236-242.
69. Goalstone, M., Carel, K., Leitner, J. W., and Draznin, B. (1997). Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway. Endocrinology 138, 5119-5124.
70. Gonda, T. A., Tu, S., and Wang, T. C. (2009). Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 8, 2005-2013.
71. Gooch, J. L., Van Den Berg, C. L., and Yee, D. (1999). Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death proliferative and antiapoptotic effects. Breast Cancer Res. Treat. 56, 1-10.
72. Gualberto, A., and Pollak, M. (2009). Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr. Drug Targets 10, 923-936.
73. Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., and Engelman, J. A. (2008). Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins. J. Clin. Invest. 118, 2609-2619.
74. Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Makela, T. P., Alessi, D. R., and Hardie, D. G. (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMPactivated protein kinase cascade. J. Biol. 2, 28.
75. Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
76. He, W., Rose, D. W., Olefsky, J. M., and Gustafson, T. A. (1998). Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. J. Biol. Chem. 273, 6860-6867.
77. Heaney, A. P., Fernando, M., Yong, W. H., and Melmed, S. (2002). Functional PPAR-gamma receptor is a novel therapeutic target for ACTHsecreting pituitary adenomas. Nat. Med. 8, 1281-1287.
78. Hemkens, L. G., Grouven, U., Bender, R., Gunster, C., Gutschmidt, S., Selke, G. W., and Sawicki, P. T. (2009). Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52, 1732-1744.
79. Herranz, D., Munoz-Martin, M., Canamero, M., Mulero, F., MartinezPastor, B., Fernandez-Capetillo, O., and Serrano, M. (2010). Sirt1 improves healthy ageing and protects from metabolic syndromeassociated cancer. Nat. Commun. 1, 3.
80. Hers, I., Vincent, E. E., and Tavare, J. M. (2011). Akt signalling in health and disease. Cell. Signal. 23, 1515-1527.
81. Heskamp, S., Van Laarhoven, H. W., Molkenboer-Kuenen, J. D., Franssen, G. M., Versleijen-Jonkers, Y. M., Oyen, W. J., Van Der Graaf, W. T., and Boerman, O. C. (2011). ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triplenegative breast cancer model. J. Nucl. Med. 51, 1565-1572.
82. Heuson, J. C., and Legros, N. (1972). Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthraceneinduced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res. 32, 226-232.
83. Hofmann, F., and Garcia-Echeverria, C. (2005). Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 10, 1041-1047.
84. Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M., Inamori, M., Tomatsu, A., Chihara, T., Shimpo, K., Nakagama, H., and Nakajima, A. (2010). Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol. Carcinog. 49, 662-671.
85. Imamura, T., Vollenweider, P., Egawa, K., Clodi, M., Ishibashi, K., Nakashima, N., Ugi, S., Adams, J. W., Brown, J. H., and Olefsky, J. M. (1999). G alpha-q/11 protein plays a key role in insulin-induced glucose transport in 3T3-L1 adipocytes. Mol. Cell. Biol. 19, 6765-6774.
86. Inoue, K., Kawahito, Y., Tsubouchi, Y., Kohno, M., Yoshimura, R., Yoshikawa, T., and Sano, H. (2001). Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun. 287, 727-732.
87. Irwin, M. L., Duggan, C., Wang, C. Y., Smith, A. W., Mctiernan, A., Baumgartner, R. N., Baumgartner, K. B., Bernstein, L., and Ballard-Barbash, R. (2011). Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J. Clin. Oncol. 29, 47-53.
88. Jensen, M., Hansen, B., De Meyts, P., Schaffer, L., and Urso, B. (2007). Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J. Biol. Chem. 282, 35179-35186.
89. Jiang, Z. Y., Lin, Y. W., Clemont, A., Feener, E. P., Hein, K. D., Igarashi, M., Yamauchi, T., White, M. F., and King, G. L. (1999). Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 104, 447-457.
90. Jiracek, J., Zakova, L., Antolikova, E., Watson, C. J., Turkenburg, J. P., Dodson, G. G., and Brzozowski, A. M. (2010). Implications for the active form of human insulin based on the structural convergence of highly active hormone analogues. Proc. Natl. Acad. Sci. U.S.A. 107, 1966-1970.
91. Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M. C., Hortobagyi, G. N., and Gonzalez-Angulo, A. M. (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27, 3297-3302.
92. Johnson, J. A., and Bowker, S. L. (2010). Intensive glycaemic control and cancer risk in type 2 diabetes: a metaanalysis of major trials. Diabetologia 54, 25-31.
93. Johnson, J. A., Majumdar, S. R., Simpson, S. H., and Toth, E. L. (2002). Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25, 2244-2248.
94. Jonasson, J. M., Ljung, R., Talback, M., Haglund, B., Gudbjornsdottir, S., and Steineck, G. (2009). Insulin glargine use and shortterm incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52, 1745-1754.
95. Kaaks, R., and Lukanova, A. (2002). Effects of weight control and physical activity in cancer prevention: role of endogenous hormone metabolism. Ann. N. Y. Acad. Sci. 963, 268-281.
96. Kawa, S., Nikaido, T., Unno, H., Usuda, N., Nakayama, K., and Kiyosawa, K. (2002). Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 24, 1-7.
97. Kiely, P. A., Leahy, M., O'gorman, D., and O'connor, R. (2005). RACK1mediated integration of adhesion and insulin-like growth factor I (IGF-I) signaling and cell migration are defective in cells expressing an IGF-I receptor mutated at tyrosines 1250 and 1251. J. Biol. Chem. 280, 7624-7633.
98. Kim, H. J., Hwang, J. Y., Choi, W. S., Lee, J. H., Chang, K. C., Nishinaka, T., Yabe-Nishimura, C., and Seo, H. G. (2007a). Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. Clin. Cancer Res. 13, 2577-2583.
99. Kim, H. J., Litzenburger, B. C., Cui, X., Delgado, D. A., Grabiner, B. C., Lin, X., Lewis, M. T., Gottardis, M. M., Wong, T. W., Attar, R. M., Carboni, J. M., and Lee, A. V. (2007b). Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol. Cell. Biol. 27, 3165-3175.
100. Kim, J. J., and Accili, D. (2002). Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm. IGF Res. 12, 84-90.
101. Kurtzhals, P., Schaffer, L., Sorensen, A., Kristensen, C., Jonassen, I., Schmid, C., and Trub, T. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49, 999-1005.
102. Laviola, L., Giorgino, F., Chow, J. C., Baquero, J. A., Hansen, H., Ooi, J., Zhu, J., Riedel, H., and Smith, R. J. (1997). The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts. J. Clin. Invest. 99, 830-837.
103. Law, J. H., Habibi, G., Hu, K., Masoudi, H., Wang, M. Y., Stratford, A. L., Park, E., Gee, J. M., Finlay, P., Jones, H. E., Nicholson, R. I., Carboni, J., Gottardis, M., Pollak, M., and Dunn, S. E. (2008). Phosphorylated insulin-like growth factori/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68, 10238-10246.
104. Lee, M. S., Kim, D., Jo, K., and Hwang, J. K. (2011). Nordihydroguaiaretic acid protects against high-fat dietinduced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem. Biophys. Res. Commun. 401, 92-97.
105. Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P. Jr., Vaughn, D. J., Nessel, L., Selby, J., and Strom, B. L. (2011). Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34, 916-922.
106. Li, F., Pham, J. D., Anderson, M. O., and Youngren, J. F. (2009). Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling. Eur. J. Pharmacol. 616, 31-37.
107. Li, M. Y., Deng, H., Zhao, J. M., Dai, D., and Tan, X. Y. (2003). Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. WorldJ. Gastroenterol. 9, 1683-1688.
108. Ligensa, T., Krauss, S., Demuth, D., Schumacher, R., Camonis, J., Jaques, G., and Weidner, K. M. (2001). A PDZ domain protein interacts with the C-terminal tail of the insulinlikegrowthfactor-1receptorbutnot with the insulin receptor. J. Biol. Chem. 276, 33419-33427.
109. Litzenburger, B. C., Creighton, C. J., Tsimelzon, A., Chan, B. T., Hilsenbeck, S. G., Wang, T., Carboni, J. M., Gottardis, M. M., Huang, F., Chang, J. C., Lewis, M. T., Rimawi, M. F., and Lee, A. V. (2011). High IGFIR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGFIR therapy. Clin. Cancer Res. 17, 2314-2327.
110. Loke, Y. K., Kwok, C. S., and Singh, S. (2011). Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342, d1309.
111. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. (2001). Insulinlike growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93, 1852-1857.
112. Macaulay, V. M., Middleton, M. R., Eckhardt, S. G., Juergens, R. A., Stephens, A. W., Poondru, S., Mccarthy, S. P., and Gadgeel, S. M. (2010). Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. J. Clin. Oncol. 28, abstr. 3016.
113. Malaguarnera, R., Frasca, F., Garozzo, A., Giani, F., Pandini, G., Vella, V., Vigneri, R., and Belfiore, A. (2011). Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J. Clin. Endocrinol. Metab. 96, 766-774.
114. Mayer, D., Shukla, A., and Enzmann, H. (2008). Proliferative effects of insulin analogues on mammary epithelial cells. Arch. Physiol. Biochem. 114, 38-44.
115. Miura, M., Surmacz, E., Burgaud, J. L., and Baserga, R. (1995). Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J. Biol. Chem. 270, 22639-22644.
116. Miyamoto, S., Nakamura, M., Shitara, K., Nakamura, K., Ohki, Y., Ishii, G., Goya, M., Kodama, K., Sangai, T., Maeda, H., Shi-Chuang, Z., Chiba, T., and Ochiai, A. (2005). Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin. Cancer Res. 11, 3494-3502.
117. Moller, D. E., Yokota, A., Caro, J. F., and Flier, J. S. (1989). Tissuespecific expression of two alternatively spliced insulin receptor mRNAs in man. Mol. Endocrinol. 3, 1263-1269.
118. Monami, M., Lamanna, C., Balzi, D., Marchionni, N., and Mannucci, E. (2009). Sulphonylureas and cancer: a case-control study. Acta Diabetol. 46, 279-284.
119. Monami, M., Lamanna, C., Marchionni, N., and Mannucci, E. (2008). Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31, 1455-1460.
120. Morcavallo, A., Gaspari, M., Pandini, G., Palummo, A., Cuda, G., Larsen, M. R., Vigneri, R., and Belfiore, A. (2011). Research resource: new and diverse substrates for the insulin receptor isoform a revealed by quantitative proteomics after stimulation with igf-ii or insulin. Mol. Endocrinol. 25, 1456-1468.
121. Morden, N. E., Liu, S. K., Smith, J., Mackenzie, T. A., Skinner, J., and Korc, M. (2011). Further Exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34, 1965-1971.
122. Mosthaf, L., Grako, K., Dull, T. J., Coussens, L., Ullrich, A., and Mcclain, D. A. (1990). Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 9, 2409-2413.
123. Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Figg, W. D., Zhou, X. P., Eng, C., Spiegelman, B. M., and Kantoff, P. W. (2000). Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 97, 10990-10995.
124. Mulligan, C., Rochford, J., Denyer, G., Stephens, R., Yeo, G., Freeman, T., Siddle, K., and O'rahilly, S. (2002). Microarray analysis of insulin and insulin-like growth factor-1 (IGF-1) receptor signaling reveals the selective up-regulation of the mitogen heparin-binding EGF-like growth factor by IGF-1. J. Biol. Chem. 277, 42480-42487.
125. Mulvihill, M. J., Cooke, A., RosenfeldFranklin, M., Buck, E., Foreman, K., Landfair, D., O'connor, M., Pirritt, C., Sun, Y., Yao, Y., Arnold, L. D., Gibson, N. W., and Ji, Q. S. (2009). Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153-1171.
126. Najjar, S. M., Blakesley, V. A., Li Calzi, S., Kato, H., Leroith, D., and Choice, C. V. (1997). Differential phosphorylation of pp120 by insulin and insulin-like growth factor-1 receptors: role for the C-terminal domain of the beta-subunit. Biochemistry 36, 6827-6834.
127. Nakae, J., Kido, Y., and Accili, D. (2001). Distinct and overlapping functions of insulin and IGF-I receptors. Endocr. Rev. 22, 818-835.
128. Nicholson, R. I., Staka, C., Boyns, F., Hutcheson, I. R., and Gee, J. M. (2004). Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer 11, 623-641.
129. Novosyadlyy, R., Lann, D. E., Vijayakumar, A., Rowzee, A., Lazzarino, D. A., Fierz, Y., Carboni, J. M., Gottardis, M. M., Pennisi, P. A., Molinolo, A. A., Kurshan, N., Mejia, W., Santopietro, S., Yakar, S., Wood, T. L., and Leroith, D. (2010). Insulinmediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 70, 741-751.
130. Novosyadlyy, R., Vijayakumar, A., Lann, D., Fierz, Y., Kurshan, N., and Leroith, D. (2009). Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation. Oncogene 28, 3477-3486.
131. O'Connor, R., Kauffmann-Zeh, A., Liu, Y., Lehar, S., Evan, G. I., Baserga, R., and Blattler, W. A. (1997). Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell. Biol. 17, 427-435.
132. O'Neill, T. J., Zhu, Y., and Gustafson, T. A. (1997). Interaction of MAD2 with the carboxyl terminus of the insulin receptor but not with the IGFIR. Evidence for release from the insulin receptor after activation. J. Biol. Chem. 272, 10035-10040.
133. Palmade, F., Sechoy-Chambon, O., Coquelet, C., and Bonne, C. (1994). Insulin-like growth factor-1 (IGF1) specifically binds to bovine lens epithelial cells and increases the number of fibronectin receptor sites. Curr. Eye Res. 13, 531-537.
134. Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., and Belfiore, A. (2002). Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 277, 39684-39695.
135. Pandini, G., Medico, E., Conte, E., Sciacca, L., Vigneri, R., and Belfiore, A. (2003). Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J. Biol. Chem. 278, 42178-42189.
136. Pandini, G., Vigneri, R., Costantino, A., Frasca, F., Ippolito, A., FujitaYamaguchi, Y., Siddle, K., Goldfine, I. D., and Belfiore, A. (1999). Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin. Cancer Res. 5, 1935-1944.
137. Pandini, G., Wurch, T., Akla, B., Corvaia, N., Belfiore, A., and Goetsch, L. (2007). Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur. J. Cancer 43, 1318-1327.
138. Papa, V., Pezzino, V., Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G. B., Brand, R., Goldfine, I. D., and Vigneri, R. (1990). Elevated insulin receptor content in human breast cancer. J. Clin. Invest. 86, 1503-1510.
139. Patel, K. M., Wright, K. L., Whittaker, P., Chakravarty, P., Watson, M. L., and Ward, S. G. (2005). Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma). Cell. Signal. 17, 1098-1110.
140. Paul, S., Dansithong, W., Kim, D., Rossi, J., Webster, N. J., Comai, L., and Reddy, S. (2006). Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing. EMBO J. 25, 4271-4283.
141. Perks, C. M., Vernon, E. G., Rosendahl, A. H., Tonge, D., and Holly, J. M. (2007). IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26, 5966-5972.
142. Pillay, T. S., Sasaoka, T., and Olefsky, J. M. (1995). Insulin stimulates the tyrosine dephosphorylation of pp125 focal adhesion kinase. J. Biol. Chem. 270, 991-994.
143. Pisani, P. (2008). Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch. Physiol. Biochem. 114, 63-70.
144. Pocock, S. J., and Smeeth, L. (2009). Insulin glargine and malignancy: an unwarranted alarm. Lancet 374, 511-513.
145. Pollak, M. (2008a). Insulin and insulinlike growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928. Pollak, M. (2008b). Targeting insulin and insulin-like growth factor signalling in oncology. Curr. Opin. Pharmacol. 8, 384-392.
146. Rakatzi, I., Stosik, M., Gromke, T., Siddle, K., and Eckel, J. (2006). Differential phosphorylation of IRS-1 and IRS-2 by insulin and IGF-I receptors. Arch. Physiol. Biochem. 112, 37-47.
147. Reeves, R., Edberg, D. D., and Li, Y. (2001). Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol. Cell. Biol. 21, 575-594.
148. Roux, P. P., and Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68, 320-344.
149. Rowe, D. L., Ozbay, T., Bender, L. M., and Nahta, R. (2008). Nordihydroguaiaretic acid, a cytotoxic insulinlike growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol. Cancer Ther. 7, 1900-1908.
150. Ruiter, R., Visser, L. E., Van Herk-Sukel, M. P., Coebergh, J. W., Haak, H. R., Geelhoed-Duijvestijn, P. H., Straus, S. M., Herings, R. M., and Stricker, B. H. (2011). Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large populationbased follow-up study. Diabetologia. doi: 10.1007/s00125-0112312-4.
151. Sacco, A., Morcavallo, A., Pandini, G., Vigneri, R., and Belfiore, A. (2009). Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology 150, 3594-3602.
152. Sachdev, D., Singh, R., FujitaYamaguchi, Y., and Yee, D. (2006). Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res. 66, 2391-2402.
153. Samani, A. A., Yakar, S., Leroith, D., and Brodt, P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47.
154. Sarbassov, D. D., Ali, S. M., and Sabatini, D. M. (2005). Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603.
155. Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X. Z., Adrian, T. E., and Pour, P. M. (2001). Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263-1270.
156. Sciacca, L., Costantino, A., Pandini, G., Mineo, R., Frasca, F., Scalia, P., Sbraccia, P., Goldfine, I. D., Vigneri, R., and Belfiore, A. (1999). Insulin receptor activation by IGFII in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18, 2471-2479.
157. Sciacca, L., Mineo, R., Pandini, G., Murabito, A., Vigneri, R., and Belfiore, A. (2002). In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21, 8240-8250.
158. Scotlandi, K. (2006). Targeted therapies in Ewing's sarcoma. Adv. Exp. Med. Biol. 587, 13-22.
159. Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., Deangelis, T., Rubin, R., Efstratiadis, A., and Baserga, R. (1994). Effect of a null mutation of the insulinlikegrowthfactorIreceptorgene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 14, 3604-3612.
160. Sertznig, P., Seifert, M., Tilgen, W., and Reichrath, J. (2007). Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J. Cell. Physiol. 212, 1-12.
161. Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., Depinho, R. A., and Cantley, L. C. (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99.
162. Shi, J., Wang, D. M., Wang, C. M., Hu, Y., Liu, A. H., Zhang, Y. L., Sun, B., and Song, J. G. (2009). Insulin receptor substrate-1 suppresses transforming growth factor-beta1-mediated epithelial-mesenchymal transition. Cancer Res. 69, 7180-7187.
163. Shimada, T., Kojima, K., Yoshiura, K., Hiraishi, H., and Terano, A. (2002). Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50, 658-664.
164. Sivakumar, R., Koga, H., Selvendiran, K., Maeyama, M., Ueno, T., and Sata, M. (2009). Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelialmesenchymal transition. Int. J. Oncol. 34, 329-338.
165. Slaaby, R., Schaffer, L., Lautrup-Larsen, I., Andersen, A. S., Shaw, A. C., Mathiasen, I. S., and Brandt, J. (2006). Hybrid receptors formed by insulin receptor (IR) and insulinlike growth factor I receptor (IGFIR) have low insulin and high IGF1 affinity irrespective of the IR splice variant. J. Biol. Chem. 281, 25869-25874.
166. Solomon, C. S., and Goalstone, M. L. (2001). Dominant negative farnesyltransferase alpha-subunit inhibits insulin mitogenic effects. Biochem. Biophys. Res. Commun. 285, 161-166.
167. Sommerfeld, M. R., Muller, G., Tschank, G., Seipke, G., Habermann, P., Kurrle, R., and Tennagels, N. (2010). In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5, e9540. doi:10.1371/journal.pone.0009540.
168. Soni, P., Lakkis, M., Poy, M. N., Fernstrom, M. A., and Najjar, S. M. (2000). The differential effects of pp120 (Ceacam 1) on the mitogenic action of insulin and insulin-like growth factor 1 are regulated by the nonconserved tyrosine 1316 in the insulin receptor. Mol. Cell. Biol. 20, 3896-3905.
169. Soos, M. A., and Siddle, K. (1989). Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem. J. 263, 553-563.
170. Stambolic, V., Suzuki, A., De La Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., and Mak, T. W. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39.
171. Steinbach, G., Kumar, S. P., Reddy, B. S., Lipkin, M., and Holt, P. R. (1993). Effects of caloric restriction and dietary fat on epithelial cell proliferation in rat colon. Cancer Res. 53, 2745-2749.
172. Strickler, H. D., Wylie-Rosett, J., Rohan, T., Hoover, D. R., Smoller, S., Burk, R. D., and Yu, H. (2001). The relation of type 2 diabetes and cancer. Diabetes Technol. Ther. 3, 263-274.
173. Tamburini, J., Chapuis, N., Bardet, V., Park, S., Sujobert, P., Willems, L., Ifrah, N., Dreyfus, F., Mayeux, P., Lacombe, C., and Bouscary, D. (2008). Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111, 379-382.
174. Tan, B. X., Yao, W. X., Ge, J., Peng, X. C., Du, X. B., Zhang, R., Yao, B., Xie, K., Li, L. H., Dong, H., Gao, F., Zhao, F., Hou, J. M., Su, J. M., and Liu, J. Y. (2011). Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 117, 5103-5111.
175. Tartare-Deckert, S., Murdaca, J., SawkaVerhelle, D., Holt, K. H., Pessin, J. E., and Van Obberghen, E. (1996). Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor and the insulin-like growth factor-1 (IGF-I) receptor: comparative study using the yeast two-hybrid system. Endocrinology 137, 1019-1024.
176. Tolcher, A. W., Sarantopoulos, J., Patnaik, A., Papadopoulos, K., Lin, C. C., Rodon, J., Murphy, B., Roth, B., Mccaffery, I., Gorski, K. S., Kaiser, B., Zhu, M., Deng, H., Friberg, G., and Puzanov, I. (2009). Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800-5807.
177. Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., and Nakajima, A. (2008). Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 99, 2136-2141.
178. Tontonoz, P., and Spiegelman, B. M. (2008). Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289-312.
179. Tran, T. T., Medline, A., and Bruce, W. R. (1996). Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev. 5, 1013-1015.
180. Ullrich, A., Bell, J. R., Chen, E. Y., Herrera, R., Petruzzelli, L. M., Dull, T. J., Gray, A., Coussens, L., Liao, Y. C., Tsubokawa, M., Mason, A., Seeburg, P. H., Grunfeld, C., Rosen, O. M., and Ramachandran, J. (1985). Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313, 756-761.
181. Ullrich, A., Gray, A., Tam, A. W., YangFeng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., Chen, E., Jacobs, S., Francke, U., Ramachandran, J., and FujitaYamaguchi, Y. (1986). Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5, 2503-2512.
182. Vainio, H., Kaaks, R., and Bianchini, F. (2002). Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur. J. Cancer Prev. 11(SUPPL 2), S94-S100.
183. Valentinis, B., Morrione, A., Taylor, S. J., and Baserga, R. (1997). Insulin-like growth factor I receptor signaling in transformation by src oncogenes. Mol. Cell. Biol. 17, 3744-3754.
184. Van Cutsem, E., and Arends, J. (2005). The causes and consequences of cancer-associated malnutrition. Eur. J. Oncol. Nurs. 9(SUPPL 2), S51-S63.
185. Vella, V., Pandini, G., Sciacca, L., Mineo, R., Vigneri, R., Pezzino, V., and Belfiore, A. (2002). A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 87, 245-254.
186. Vigneri, P., Frasca, F., Sciacca, L., Frittitta, L., and Vigneri, R. (2006). Obesity and cancer. Nutr. Metab. Cardiovasc. Dis. 16, 1-7.
187. Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., and Vigneri, R. (2009). Diabetes and cancer. Endocr. Relat. Cancer 16, 1103-1123.
188. Vincent, M. T., Carroll, R. J., Hammer, R. E., Chan, S. J., Guz, Y., Steiner, D. F., and Teitelman, G. (1995). A transgene coding for a human insulin analog has a mitogenic effect on murine embryonic beta cells. Proc. Natl. Acad. Sci. U.S.A. 92, 6239-6243.
189. Wan, X., Harkavy, B., Shen, N., Grohar, P., and Helman, L. J. (2007). Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932-1940.
190. Webster, N. J., Resnik, J. L., Reichart, D. B., Strauss, B., Haas, M., and Seely, B. L. (1996). Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res. 56, 2781-2788.
191. Whittaker, J., and Whittaker, L. (2005). Characterization of the functional insulin binding epitopes of the full length insulin receptor. J. Biol. Chem. 280, 20932-20936.
192. Wicha, M. S., Liu, S., and Dontu, G. (2006). Cancer stem cells: an old idea a paradigm shift. Cancer Res. 66, 1883-1890; discussion 1895-1886.
193. Yamaguchi, Y., Flier, J. S., Benecke, H., Ransil, B. J., and Moller, D. E. (1993). Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology 132, 1132-1138.
194. Youngren, J. F., Gable, K., Penaranda, C., Maddux, B. A., Zavodovskaya, M., Lobo, M., Campbell, M., Kerner, J., and Goldfine, I. D. (2005). Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res. Treat. 94, 37-46.
195. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., and Pollak, M. (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273.
196. Zeng, L., Sachdev, P., Yan, L., Chan, J. L., Trenkle, T., Mcclelland, M., Welsh, J., and Wang, L. H. (2000). Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol. Cell. Biol. 20, 9212-9224.
197. Zhang, H., Pelzer, A. M., Kiang, D. T., andYee, D. (2007). Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 67, 391-397.
198. Zhu, Z., Jiang, W., Thompson, M. D., Mcginley, J. N., and Thompson, H. J. (2011). Metformin as an energy restriction mimetic agent for breast cancer prevention. J. Carcinog. 10, 17.